Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global revolution, integrating into economic and social development to address major challenges such as health, climate change, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Bioeconomic Development," indicating a trillion-yuan market potential in the bioeconomy [4] Industry Market Dynamics - The synthetic biology index decreased by 9.66% to 1437.31 during the week of April 5-11, 2025, underperforming compared to the Shanghai Composite Index, which fell by 1.62%, and the ChiNext Index, which dropped by 4.21% [5][17] - The top five performing companies in the synthetic biology sector during this period were: - Novozymes (+27%) - Shandong Heda (+10%) - Yaxing Co. (+10%) - Pro Pharma (+3%) - Huafeng Chemical (+2%) [18] - The bottom five performing companies were: - Xinri Hengli (-18%) - Kasei Biotech (-12%) - Yaborn Chemical (-9%) - Berry Genomics (-7%) - Blue Biological (-6%) [22] Company Business Developments - Anhui Pucan launched the world's largest CO₂-based polycarbonate production facility, with an annual capacity of 50,000 tons, expected to generate sales of 1.5 billion yuan [23] - Huafeng Chemical plans to acquire two subsidiaries to integrate the polyurethane supply chain, with projected combined revenue exceeding 6.4 billion yuan in 2024 [23] - Tianchen Company signed a contract for a 100,000 tons/year bioethanol project in Egypt, marking its first venture into the North African market [24] Industry Financing Tracking - Synthetic biology companies are accelerating financing, with nearly 100 firms completing new rounds of funding since the beginning of 2025. Zhongsheng Suyuan Biotechnology raised 235 million yuan in its B round, focusing on iPSC-derived cell therapies [28][29] Company R&D Directions - Jinbo Biotech received approval for its recombinant type III human collagen injection product, marking a breakthrough in high-end medical aesthetics [31] - CellX's mushroom mycelium protein received FDA GRAS certification, allowing entry into the U.S. market [31] - MycoTechnology's truffle sweet protein ClearHT received FEMA GRAS certification, showcasing advancements in natural flavoring and health foods [32]

昆山亚香香料股份有限公司（以下简称"公司"）第三届董事会、监事会及高级 管理人员任期于 2025 年 4 月 10 日届满，公司正在积极筹备换届工作。鉴于公司新一 届董事、监事及高级管理人员候选人的提名工作仍在进行中，为保持相关工作的准确 性、连续性和稳定性，公司董事会、监事会换届选举工作将适当延期，公司董事会各 专门委员会委员和高级管理人员的任期也将相应顺延。公司将积极推进董事会、监事 会及高级管理人员的换届选举工作，并在相关事宜确定后，及时履行相应的信息披露 义务。 证券代码：301220 证券简称：亚香股份 公告编号：2025-014 昆山亚香香料股份有限公司 关于董事会、监事会和高级管理人员延迟换届的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 在换届选举工作完成之前，公司第三届董事会、监事会全体成员及高级管理人员 将依照法律、行政法规和《公司章程》等相关规定，继续履行该届董事、监事及高级 管理人员的义务与职责。公司董事会、监事会及高级管理人员的延迟换届不会影响公 司的正常经营。 特此公告。 昆山亚香香料股份有限公司 董事会 2025 年 4 ...

Core Viewpoint - The recent series of share reduction announcements by major shareholders and executives of Yaxiang Co., Ltd. has raised concerns about the company's future development amidst declining performance metrics [1][2]. Group 1: Share Reduction Details - Major shareholder Kunshan Dinglong Bohui Investment Management plans to reduce its holdings by up to 2.424 million shares, accounting for 3% of the total share capital, within 90 days after the announcement [1]. - Executives including the board secretary and several directors also plan to reduce their holdings, with a total reduction of 0.35% [1]. - The timing of these reductions coincides with the company's stock price being at historical highs, suggesting that the reductions may be a strategy to lock in profits [1][2]. Group 2: Company Performance - In 2023, Yaxiang Co., Ltd. experienced a 10.66% decline in revenue and a 39.18% drop in net profit [2]. - For the first three quarters of 2024, the company reported a revenue increase of 21.37% to 576 million yuan, but the net profit attributable to shareholders fell by 34.58%, indicating a situation of increasing revenue without corresponding profit growth [2]. - The significant drop in performance metrics may contribute to the shareholders' decision to reduce their stakes, reflecting concerns about the company's future prospects [2]. Group 3: Market Reaction and Implications - Following the announcements, Yaxiang Co., Ltd.'s stock price fell by over 11% during intraday trading on April 3, indicating a negative market reaction [2]. - The concentrated share reduction may lead to increased volatility in the stock price and could raise questions about the company's internal governance and future development [2][3]. - The company is urged to focus on enhancing its core competitiveness and improving performance to regain market confidence [3].

Group 1: 华盛锂电 - Company plans to invest in a project to produce 60,000 tons of vinyl carbonate annually, with the first phase targeting 30,000 tons [1] - Total investment for the project is approximately 950 million yuan, funded by the company's own or raised funds [1][2] Group 2: 万里扬 - Shareholder plans to reduce holdings by up to 1.5% of the company's total shares, equating to a maximum of 19.69 million shares [3] - The reduction is due to the shareholder's own funding needs [3][4] Group 3: 云南旅游 - Company intends to raise no more than 191 million yuan through a private placement of up to 304 million shares [5] - Funds will be used for the construction of a cultural tourism equipment industrial park and to repay debts [5][6] Group 4: 冠农股份 - Company reported a 71.58% decline in net profit for 2024, amounting to 205 million yuan [9] - Revenue decreased by 11.15% to 3.863 billion yuan, with a proposed cash dividend of 0.8 yuan per 10 shares [9][10] Group 5: 华光新材 - Company achieved a 93.78% increase in net profit for 2024, totaling 80.6174 million yuan [11] - Revenue grew by 35.52% to 1.918 billion yuan, with a proposed cash dividend of 2.77 yuan per 10 shares [11][12] Group 6: 南大光电 - Company reported a 28.15% increase in net profit for 2024, reaching 271 million yuan [13] - Revenue increased by 38.08% to 2.352 billion yuan, with a proposed cash dividend of 1 yuan per 10 shares and a stock bonus of 2 shares for every 10 shares held [13][14] Group 7: 博瑞医药 - Company experienced a 6.57% decrease in net profit for 2024, amounting to 189 million yuan [15] - Revenue increased by 8.74% to 1.283 billion yuan, with a proposed cash dividend of 0.96 yuan per 10 shares [15][16] Group 8: 贵州茅台 - Company reported a 15.38% increase in net profit for 2024, totaling 862 million yuan [17] - Revenue grew by 15.71% to 170.9 billion yuan, with a proposed cash dividend of 276.24 yuan per 10 shares [17][18] Group 9: 西部建设 - Company reported a net loss of 263 million yuan for 2024, compared to a profit of 645 million yuan in 2023 [19] - Revenue decreased by 11.01% to 20.347 billion yuan, with a proposed cash dividend of 1.25 yuan per 10 shares [19][20] Group 10: 锡业股份 - Company achieved a 2.55% increase in net profit for 2024, totaling 1.444 billion yuan [21] - Revenue slightly decreased by 0.91% to 41.973 billion yuan, with a proposed cash dividend of 1.9 yuan per 10 shares [21][22] Group 11: 海天味业 - Company reported a 12.75% increase in net profit for 2024, amounting to 6.344 billion yuan [23] - Revenue increased by 9.53% to 26.901 billion yuan, with a proposed cash dividend of 8.6 yuan per 10 shares [23][24] Group 12: 台基股份 - Company experienced an 18.77% decrease in net profit for 2024, totaling 25.2935 million yuan [25] - Revenue increased by 10.76% to 354 million yuan, with a proposed cash dividend of 0.8 yuan per 10 shares [25][26] Group 13: 金盘科技 - Company reported a 13.82% increase in net profit for 2024, amounting to 574 million yuan [27] - Revenue grew by 3.5% to 6.901 billion yuan, with a proposed cash dividend of 5.06 yuan per 10 shares [27][28] Group 14: 中油资本 - Company reported an 8.14% decrease in net profit for 2024, totaling 4.652 billion yuan [29] - Revenue slightly increased by 0.08% to 39.024 billion yuan, with a proposed cash dividend of 0.57 yuan per 10 shares [29][30] Group 15: 锐捷网络 - Company achieved a 43.09% increase in net profit for 2024, amounting to 574 million yuan [31] - Revenue increased by 1.36% to 11.699 billion yuan, with a proposed cash dividend of 6.06 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [31][32] Group 16: 华瓷股份 - Company reported a 14.21% increase in net profit for 2024, totaling 205 million yuan [33] - Revenue grew by 8.79% to 1.34 billion yuan, with a proposed cash dividend of 4 yuan per 10 shares [33][34] Group 17: 金龙羽 - Company experienced a 14.14% decrease in net profit for 2024, amounting to 14 million yuan [35] - Revenue decreased by 6.53% to 3.675 billion yuan, with a proposed cash dividend of 3 yuan per 10 shares [35][36] Group 18: 恒帅股份 - Company reported a 5.75% increase in net profit for 2024, totaling 214 million yuan [37] - Revenue increased by 4.21% to 962 million yuan, with a proposed cash dividend of 4 yuan per 10 shares and a stock bonus of 4 shares for every 10 shares held [37][38] Group 19: 爱玛科技 - Company expects a 25.12% increase in net profit for the first quarter of 2025, amounting to 605 million yuan [39] - Main business includes the development, production, and sales of electric bicycles and motorcycles [39][40] Group 20: 西王食品 - Company reported a net loss of 444 million yuan for 2024, compared to a loss of 16.8658 million yuan in 2023 [41] - Revenue decreased by 9.43% to 4.972 billion yuan [41][42]

Core Viewpoint - The announcement from Yaxiang Co., Ltd. details the planned share reductions by several executives, indicating a potential shift in insider sentiment regarding the company's stock performance [1]. Summary by Relevant Sections Executive Share Reductions - Director and Vice President Chen Qing plans to reduce his holdings by up to 73,100 shares, representing 0.09% of the total share capital, within 90 days after a 15-day waiting period [1]. - Director and Vice President Fang Long intends to sell up to 75,400 shares, also accounting for 0.09% of the total share capital, under the same conditions [1]. - Director Xia Xueqi will reduce her holdings by a maximum of 30,000 shares, which is 0.04% of the total share capital, following the same timeline [1]. - Supervisor Wang Bingliang is set to decrease his shares by up to 108,200 shares, representing 0.14% of the total share capital, adhering to the same 90-day period after the waiting period [1].

证券代码：301220 证券简称：亚香股份 公告编号：2025-012 昆山亚香香料股份有限公司 关于公司部分董事、监事间接减持计划的预披露公告 公司董事兼副总经理陈清、方龙；公司董事夏雪琪；监事王秉良保证向公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、间接持有昆山亚香香料股份有限公司（以下简称"公司"）股份 292,499 股（占剔除公司回购专用账户 872,900 股后的总股本比例的 0.37%）的公司董事、 副总经理陈清先生，自本公告披露之日起 15 个交易日后的连续 90 个自然日内， 以集中竞价方式或大宗交易方式不低于公司发行价减持公司股份，减持股份总数 不超过 73,100 股（占公司总股本比例 0.09%）。 2、间接持有公司股份 301,874 股（占剔除公司回购专用账户 872,900 股后的 总股本比例的 0.38%）的公司董事、副总经理方龙先生，自本公告披露之日起 15 个交易日后的连续 90 个自然日内，以集中竞价方式或大宗交易方式不低于公司 发行价减持公司股份，减持股份总 ...

证券代码：301220 证券简称：亚香股份 公告编号：2025-013 昆山亚香香料股份有限公司 关于公司董事兼董事会秘书减持计划的预披露公告 公司董事、董事会秘书盛军保证向公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、持有公司股份 400,000 股（占剔除公司回购专用账户 872,900 股后的总股 本比例的 0.50%）的公司董事兼董事会秘书盛军先生，计划在本公告披露之日起 15 个交易日后的 90 天内，以集中竞价方式或大宗交易方式不低于公司发行价减 持公司股份，减持股份总数不超过 100,000 股（占公司总股本比例 0.12%）。 若在减持计划实施期间内公司发生送红股、资本公积转增股本等股本变动事 项时，将对上述减持数量进行相应调整。 公司近日收到盛军先生出具的《股份减持计划告知函》，现将有关情况公告 如下： | 序号 | 股东 | 股东身份 | 持股总 持股总 | 持有无限售条 | 持有有限售条 | | --- | --- | --- | --- | --- | --- | | | ...

证券代码：301220 证券简称：亚香股份 公告编号：2025-011 昆山亚香香料股份有限公司 关于持股5%以上股东股份减持计划预披露的公告 股东昆山鼎龙博晖投资管理企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 注：本次拟减持股份数量中包含公司监事徐平通过间接持有的公司股份 3,900 股（监事徐平通过鼎龙博晖间接持有公司股份总计 15,750 股）。 持有昆山亚香香料股份有限公司（以下简称"公司"）股份 5,538,300 股（占 剔除公司回购专用账户 872,900 股后的总股本比例的 6.93%）的昆山鼎龙博晖投 资管理企业（有限合伙）（以下简称"鼎龙博晖"）计划自本公告披露之日起 15 个交易日后的连续 90 个自然日内合计减持不超过 2,424,000 股，不超过公司总股 本比例 3%。其中通过集中竞价交易方式减持公司股份不超过 808,000 股，不超 过公司总股本比例 1%；通过大宗交易方式减持公司股份不超过 1,616,000 股，不 超过公司总股本比例 2% ...

北京市中伦（上海）律师事务所 关于昆山亚香香料股份有限公司 2025 年第一次临时股东大会的 法律意见书 二〇二五年四月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 致：昆山亚香香料股份有限公司 根据《中华人民共和国公司法》（下称"《公司法》"）、《中华人民共和国证券 法》、《上市公司股东大会规则》及其他相关法律、法规、规章和规范性文件，以 及《公司章程》相关规定，北京市中伦（上海）律师事务所（下称"本所"）受昆 山亚香香料股份有限公司（下称"公司"）委托，指派律师出席公司 2025 ...

昆山亚香香料股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无新增、变更及否决议案的情况； 2、本次股东大会不涉及变更以往股东大会已通过决议的情况。 证券代码：301220 证券简称：亚香股份 公告编号：2025-010 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议时间：2025年4月1日（星期二）14:30。 网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进行网络投 票的具体时间为：2025年4月1日9:15-9:25，9:30-11:30，13:00-15:00；通过深交所互联 网投票系统（http://wltp.cninfo.com.cn）进行网络投票的具体时间为：2025年4月1日9:15- 15:00期间的任意时间。 2、现场会议召开地点：昆山市玉山镇晨丰路201号公司会议室 6、会议召开的合法合规性：本次股东大会会议的召集、召开与表决程序符合《中 3、会议召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司董事会 5 ...